AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1463176 — intervention group
Group type: COMPARATOR
Intervention: Conventional thiopentone/isoflurane/nitrous oxide anaesthesia
Number of subjects: 50
Study 3937501 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg capsule of nifedipine
Number of subjects: 47
Study 3937501 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 capsules (20 mg) of nifedipine
Number of subjects: 47
Study 3937501 — intervention group
Group type: COMPARATOR
Intervention: 20 mg tablet of nifedipine
Number of subjects: 47
Study 3937501 — intervention group
Group type: COMPARATOR
Intervention: 40 mg tablet of nifedipine
Number of subjects: 47
Study 3937501 — intervention group
Group type: COMPARATOR
Intervention: 60 mg tablet of nifedipine
Number of subjects: 47
Study 3937501 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 X 20 mg daily of the tablet form of nifedipine
Number of subjects: 47
Study 3937501 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 X 40 mg of the nifedipine tablets
Number of subjects: 47
Study 30006694 — intervention group
Group type: EXPERIMENTAL
Intervention: Centhaquin 0.015 mg/kg
Number of subjects: 20
Study 30006694 — intervention group
Group type: COMPARATOR
Intervention: Control (group CO)
Number of subjects: 20
Study 29484808 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol supplementation
Number of subjects: 112
Study 29484808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 25457095 — intervention group
Group type: EXPERIMENTAL
Intervention: Love-inducing condition (dummy survey about love and romantic behavior)
Number of subjects: 40
Study 25457095 — intervention group
Group type: COMPARATOR
Intervention: Control condition (neutral dummy survey on odd jobs)
Number of subjects: 40
Study 25457095 — intervention group
Group type: EXPERIMENTAL
Intervention: Love-inducing condition
Number of subjects: 40
Study 25457095 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 40
Study 22712452 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable Priority (VP) training
Number of subjects: 24
Study 22712452 — intervention group
Group type: COMPARATOR
Intervention: Fixed Priority (FP) training
Number of subjects: 24
Study 20378503 — intervention group
Group type: EXPERIMENTAL
Intervention: pegfilgrastim 6 mg
Number of subjects: 241
Study 20378503 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 241
Study 18022579 — intervention group
Group type: EXPERIMENTAL
Intervention: T cell depletion and cyclosporine (TCD)
Number of subjects: 404
Study 18022579 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate/cyclosporine (M/C)
Number of subjects: 404
Study 15705376 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine (NAC) 1.2 g/d with clomiphene citrate (CC) 100 mg/d for 5 days
Number of subjects: 150
Study 15705376 — intervention group
Group type: COMPARATOR
Intervention: Placebo with clomiphene citrate (CC) 100 mg/d for 5 days
Number of subjects: 150
Study 12849761 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopaminergic medication (L-Dopa), specific dosage and duration not mentioned
Number of subjects: 0
Study 12849761 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of dopaminergic medication (off medication)
Number of subjects: 0
Study 10533471 — intervention group
Group type: EXPERIMENTAL
Intervention: Formestane (250 mg intramuscularly every 2 weeks)
Number of subjects: 177
Study 10533471 — intervention group
Group type: COMPARATOR
Intervention: Megestrol acetate (160 mg orally daily)
Number of subjects: 177
Study 8901143 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of chlorprothixene (100 mg)
Number of subjects: 8
Study 8901143 — intervention group
Group type: COMPARATOR
Intervention: Oral aqueous solution of chlorprothixene (100 mg)
Number of subjects: 8
Study 8901143 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated tablet of chlorprothixene (100 mg)
Number of subjects: 8
Study 8901143 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspension of chlorprothixene (100 mg)
Number of subjects: 8
Study 1880883 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine-exposed infants
Number of subjects: 554
Study 1880883 — intervention group
Group type: COMPARATOR
Intervention: Unexposed infants
Number of subjects: 554
Study 1880883 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine-exposed infants awaiting home and social evaluation or foster care placement
Number of subjects: 554
Study 1880883 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine-exposed infants (specifically crack exposure)
Number of subjects: 554
Study 1880883 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine-exposed infants (exposed to other illicit substances)
Number of subjects: 554
Study 1880883 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine-exposed infants (other forms of cocaine)
Number of subjects: 554
Study 7104809 — intervention group
Group type: EXPERIMENTAL
Intervention: High volume low pressure cuffed tubes
Number of subjects: 56
Study 7104809 — intervention group
Group type: COMPARATOR
Intervention: Low volume high pressure cuffed tubes
Number of subjects: 56
Study 30590726 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 611
Study 30590726 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery (CABG)
Number of subjects: 611
Study 30590726 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment (MT)
Number of subjects: 611
Study 30590726 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality incidence
Number of subjects: 611
Study 30590726 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary endpoint (composite of overall death and myocardial infarction)
Number of subjects: 611
Study 29385610 — intervention group
Group type: COMPARATOR
Intervention: Cottonseed hulls (CSH; control)
Number of subjects: 48
Study 29385610 — intervention group
Group type: EXPERIMENTAL
Intervention: Ground woody plants (redberry, blueberry, one-seed, eastern red cedar, mesquite)
Number of subjects: 48
Study 25778615 — intervention group
Group type: COMPARATOR
Intervention: Aripiprazole
Number of subjects: 17
Study 25778615 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 17
Study 25778615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 23886884 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral assistant LESS UVA (TALUVA)
Number of subjects: 10
Study 23886884 — intervention group
Group type: COMPARATOR
Intervention: Conventional LESS UVA (CLUVA)
Number of subjects: 10
Study 23886884 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 10
Study 21840651 — intervention group
Group type: EXPERIMENTAL
Intervention: 350 mg carisoprodol
Number of subjects: 15
Study 21840651 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oxycodone
Number of subjects: 15
Study 21840651 — intervention group
Group type: EXPERIMENTAL
Intervention: 350 mg carisoprodol followed by 10 mg oxycodone after 60 min
Number of subjects: 15
Study 21840651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 19703819 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg) plus atorvastatin (10 mg) daily for 6 months
Number of subjects: 50
Study 19703819 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (300 mg) plus atorvastatin (10 mg) daily for 6 months
Number of subjects: 50
Study 18025296 — intervention group
Group type: EXPERIMENTAL
Intervention: Antecedent hypertension
Number of subjects: 14703
Study 18025296 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated blood pressure (n=1226)
Number of subjects: 14703
Study 15922565 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological motion task
Number of subjects: 0
Study 15922565 — intervention group
Group type: COMPARATOR
Intervention: Global-form task
Number of subjects: 0
Study 15922565 — intervention group
Group type: EXPERIMENTAL
Intervention: Social functioning
Number of subjects: 0
Study 12543748 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferior sector
Number of subjects: 19
Study 12543748 — intervention group
Group type: COMPARATOR
Intervention: Superior sector
Number of subjects: 19
Study 11038407 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocapnic hypoxia with placebo
Number of subjects: 10
Study 11038407 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocapnic hypoxia with beta-blockade
Number of subjects: 10
Study 11038407 — intervention group
Group type: COMPARATOR
Intervention: Air breathing with placebo
Number of subjects: 10
Study 11038407 — intervention group
Group type: COMPARATOR
Intervention: Air breathing with beta-blockade
Number of subjects: 10
Study 9042316 — intervention group
Group type: EXPERIMENTAL
Intervention: Methioninase (5,000 units, 2-hour infusion)
Number of subjects: 3
Study 9042316 — intervention group
Group type: EXPERIMENTAL
Intervention: Methioninase (10,000 units, 2-hour infusion)
Number of subjects: 3
Study 9042316 — intervention group
Group type: EXPERIMENTAL
Intervention: Methioninase (20,000 units, 10-hour infusion)
Number of subjects: 3
Study 1994422 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium-enhanced fat-saturation (FS) SE MR imaging
Number of subjects: 43
Study 1994422 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium-enhanced short TR/TE conventional SE
Number of subjects: 43
Study 1994422 — intervention group
Group type: COMPARATOR
Intervention: Unenhanced short TR/TE conventional SE
Number of subjects: 43
Study 1994422 — intervention group
Group type: COMPARATOR
Intervention: Unenhanced long TR/TE conventional SE
Number of subjects: 43
Study 1994422 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium-enhanced FS SE sequence
Number of subjects: 43
Study 1994422 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined pre- and postcontrast short TR/TE FS SE images
Number of subjects: 43
Study 1994422 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium-enhanced FS SE MR sequence
Number of subjects: 43
Study 6147066 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-directed prolonged exposure in vivo (PE)
Number of subjects: 73
Study 6147066 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamically oriented supportive therapy (ST)
Number of subjects: 73
Study 6147066 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation therapy (R)
Number of subjects: 73
Study 6147066 — intervention group
Group type: COMPARATOR
Intervention: Basal therapy (standardized information, self-exposure instructions, and anxiolytic medication)
Number of subjects: 73
Study 31389340 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Telesimulation Unit (MTU)
Number of subjects: 69
Study 31389340 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional face-to-face training
Number of subjects: 69
Study 31389340 — intervention group
Group type: COMPARATOR
Intervention: Mobile Telesimulation Unit (MTU) and Traditional face-to-face training
Number of subjects: 69
Study 31021852 — intervention group
Group type: EXPERIMENTAL
Intervention: Hair tenofovir (TFV) levels
Number of subjects: 71
Study 27984542 — intervention group
Group type: EXPERIMENTAL
Intervention: Right anodal/left cathodal OP tDCS (2 mA, 12 min)
Number of subjects: 12
Study 27984542 — intervention group
Group type: EXPERIMENTAL
Intervention: Left anodal/right cathodal OP tDCS (2 mA, 12 min)
Number of subjects: 12
Study 27984542 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (15 s)
Number of subjects: 12
Study 26146796 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated stent introducer with a modified hybrid metal stent (DH group, n=16)
Number of subjects: 32
Study 26146796 — intervention group
Group type: COMPARATOR
Intervention: Conventional 8.5F biliary metal stent introducer with a fully covered metal stent (FC group, n=16)
Number of subjects: 32
Study 24132900 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome-Wide Association Study (GWAS) for atypical psychosis
Number of subjects: 47
Study 24132900 — intervention group
Group type: COMPARATOR
Intervention: Gene-based analysis of SZ
Number of subjects: 47
Study 21470906 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive e-drug calculations package
Number of subjects: 229
Study 18343920 — intervention group
Group type: EXPERIMENTAL
Intervention: Different arm positions and radiographic beam orientations
Number of subjects: 30
Study 16865863 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 U/brow of botulinum toxin type A
Number of subjects: 40
Study 16865863 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 U/brow of botulinum toxin type A
Number of subjects: 40
Study 12789898 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10685748 — intervention group
Group type: EXPERIMENTAL
Intervention: Braintree polyethylene glycol (PEG) laxative 17 g
Number of subjects: 151
Study 10685748 — intervention group
Group type: COMPARATOR
Intervention: Dextrose placebo
Number of subjects: 151
Study 9157586 — intervention group
Group type: EXPERIMENTAL
Intervention: rHDL (40 mg/kg, given as a 4 h infusion starting 3.5 h prior to LPS injection)
Number of subjects: 8
Study 9157586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9157586 — intervention group
Group type: EXPERIMENTAL
Intervention: rHDL
Number of subjects: 8
Study 8146916 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinetic positioning (KIN)
Number of subjects: 22
Study 3453715 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen 2 mg/d with desensitization
Number of subjects: 48
Study 3453715 — intervention group
Group type: COMPARATOR
Intervention: Specific hyposensitization treatment
Number of subjects: 48
Study 31594193 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait training with auditory feedback (30 minutes, 5 times a week, for 4 weeks)
Number of subjects: 20
Study 31594193 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait training with auditory feedback
Number of subjects: 20
Study 31594193 — intervention group
Group type: COMPARATOR
Intervention: Conventional gait training (30 minutes, 5 times a week, for 4 weeks)
Number of subjects: 20
Study 29707524 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter drainage combined with ozone (group II)
Number of subjects: 60
Study 29707524 — intervention group
Group type: COMPARATOR
Intervention: Catheter drainage alone (group I)
Number of subjects: 60
Study 28033355 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group 1 (lesson promoting active transport)
Number of subjects: 441
Study 28033355 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group 2 (lesson promoting active transport + Facebook group membership)
Number of subjects: 441
Study 28033355 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group 1
Number of subjects: 441
Study 28033355 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular course 'Driving Licence at School')
Number of subjects: 441
Study 24047189 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographically guided ibuprofen treatment
Number of subjects: 49
Study 24047189 — intervention group
Group type: COMPARATOR
Intervention: Standard ibuprofen treatment
Number of subjects: 49
Study 22486722 — intervention group
Group type: EXPERIMENTAL
Intervention: BioCell Collagen (BCC) 2 g
Number of subjects: 80
Study 22486722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 20507953 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive renal replacement therapy
Number of subjects: 415
Study 20507953 — intervention group
Group type: COMPARATOR
Intervention: Less intensive renal replacement therapy
Number of subjects: 415
Study 18783298 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Number of subjects: 53
Study 15928285 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI using radiofrequency ablation
Number of subjects: 70
Study 15928285 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic drug treatment
Number of subjects: 70
Study 12709127 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue counter analysis combined with machine learning algorithms (CART and 1-NN)
Number of subjects: 369
Study 12709127 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold value of 27.4% of elements suggestive for malignancy
Number of subjects: 369
Study 10480205 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose (200 units Botox per leg)
Number of subjects: 33
Study 10480205 — intervention group
Group type: COMPARATOR
Intervention: Low-dose (100 units Botox per leg)
Number of subjects: 33
Study 8911559 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg paroxetine daily
Number of subjects: 100
Study 8911559 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg imipramine daily
Number of subjects: 100
Study 8911559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 1810657 — intervention group
Group type: EXPERIMENTAL
Intervention: xylitol (9.9%) and glycerol (20%) dentifrice
Number of subjects: 76
Study 1810657 — intervention group
Group type: COMPARATOR
Intervention: sorbitol (28%) dentifrice
Number of subjects: 76
Study 1810657 — intervention group
Group type: COMPARATOR
Intervention: comparison between xylitol/glycerol and sorbitol dentifrices
Number of subjects: 76
Study 7362377 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine hydrochloride (45 mg)
Number of subjects: 7
Study 7362377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 31467191 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP withdrawal
Number of subjects: 70
Study 29080198 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 60
Study 29080198 — intervention group
Group type: COMPARATOR
Intervention: Sham-acupuncture
Number of subjects: 60
Study 26013859 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified double tracks anastomosis
Number of subjects: 763
Study 26013859 — intervention group
Group type: COMPARATOR
Intervention: Esophageal gastric stump end-to-side anastomosis
Number of subjects: 763
Study 26013859 — intervention group
Group type: COMPARATOR
Intervention: Radical total gastrectomy with esophageal jejunum Roux-en-Y anastomosis
Number of subjects: 763
Study 26013859 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 763
Study 22473731 — intervention group
Group type: EXPERIMENTAL
Intervention: self-help coping intervention (written self-help coping leaflet)
Number of subjects: 1958
Study 17613971 — intervention group
Group type: EXPERIMENTAL
Intervention: Residential Treatment (RT)
Number of subjects: 160
Study 17613971 — intervention group
Group type: COMPARATOR
Intervention: Outpatient Treatment (OP)
Number of subjects: 160
Study 15462690 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 5 mg
Number of subjects: 135
Study 15462690 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg
Number of subjects: 135
Study 15462690 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 5 mg and 10 mg
Number of subjects: 135
Study 15462690 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 135
Study 11304773 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized education and coaching intervention (20-minute session)
Number of subjects: 67
Study 11304773 — intervention group
Group type: COMPARATOR
Intervention: Standardized instruction on controlling pain (control group)
Number of subjects: 67
Study 9382964 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (0.1 IU x kg(‐1) x day(‐1)) for 4 days
Number of subjects: 8
Study 9382964 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoid (50 mg/d) for 4 days
Number of subjects: 8
Study 9382964 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone plus glucocorticoid
Number of subjects: 8
Study 9382964 — intervention group
Group type: COMPARATOR
Intervention: Control (saline injections for 4 days)
Number of subjects: 8
Study 8390369 — intervention group
Group type: COMPARATOR
Intervention: 20 mg bisoprolol p.o. (pretreatment)
Number of subjects: 8
Study 8390369 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg celiprolol p.o.
Number of subjects: 8
Study 3548809 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypo-osmolar formulation using polyvinylpyrrolidone and hydroxyethyl cellulose
Number of subjects: 2
Study 3548809 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypo-osmolar preparations of BJ6
Number of subjects: 2
Study 3548809 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypromellose
Number of subjects: 2
Study 3548809 — intervention group
Group type: COMPARATOR
Intervention: Iso-osmolar equivalents
Number of subjects: 2
Study 30556583 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive Training for Depression (D-MCT)
Number of subjects: 84
Study 30556583 — intervention group
Group type: COMPARATOR
Intervention: General Health Training (HT)
Number of subjects: 84
Study 29986448 — intervention group
Group type: COMPARATOR
Intervention: Shooters with blood lead levels (BLL) ≥ 5 µg/dL
Number of subjects: 118
Study 29986448 — intervention group
Group type: EXPERIMENTAL
Intervention: Shooters
Number of subjects: 118
Study 29986448 — intervention group
Group type: EXPERIMENTAL
Intervention: Shooters with BLL ≥ 10 µg/dL
Number of subjects: 118
Study 27094107 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting program (ADAPT)
Number of subjects: 0
Study 27094107 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 24428468 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-450/r (150 mg of ABT-450 and 100 mg of ritonavir) plus ribavirin for 8 weeks
Number of subjects: 571
Study 24428468 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-450/r (150 mg of ABT-450 and 100 mg of ritonavir) plus ribavirin for 12 weeks
Number of subjects: 571
Study 24428468 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment subgroups (various regimens of direct-acting antiviral agents and ribavirin)
Number of subjects: 571
Study 22774206 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg daily by mouth
Number of subjects: 15
Study 21349048 — intervention group
Group type: EXPERIMENTAL
Intervention: YuangongCu365
Number of subjects: 0
Study 21349048 — intervention group
Group type: EXPERIMENTAL
Intervention: TCu380A
Number of subjects: 0
Study 21349048 — intervention group
Group type: EXPERIMENTAL
Intervention: MLCu375
Number of subjects: 0
Study 17712755 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid monotherapy for 9 months (group A)
Number of subjects: 926
Study 17712755 — intervention group
Group type: COMPARATOR
Intervention: Isoniazid plus rifampin for 4 months (group B)
Number of subjects: 926